On the other hand, the concentrations of Tau (as a general marker of neuronal loss) and phosphorylated Tau181 were generally higher compared to controls but lower compared to AD at the cohort levels, reflecting a subpopulation of CAA with concomitant advanced AD neuropathologic change [251,252]. The gene discussed is MAPT; the disease is Alzheimer disease.